CoChat

A protein tertiary structure mimetic modulator of the Hippo signalling pathway

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Transcription factors are key protein effectors in the regulation of gene transcription, and in many cases their activity is regulated via a complex network of protein–protein interactions (PPI). The chemical modulation of transcription factor activity is a long-standing goal in drug discovery but hampered by the difficulties associated with the targeting of PPIs, in particular when extended and flat protein interfaces are involved. Peptidomimetics have been applied to inhibit PPIs, however with variable success, as for certain interfaces the mimicry of a single secondary structure element is insufficient to obtain high binding affinities. Here, we describe the design and characterization of a stabilized protein tertiary structure that acts as an inhibitor of the interaction between the transcription factor TEAD and its co-repressor VGL4, both playing a central role in the Hippo signalling pathway. Modification of the inhibitor with a cell-penetrating entity yielded a cell-permeable proteomimetic that activates cell proliferation via regulation of the Hippo pathway, highlighting the potential of protein tertiary structure mimetics as an emerging class of PPI modulators.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-19224-8

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Structure-based design was applied to stabilize a two-helix motif. a Crystal structure of the VGL4–TEAD (PDB: 4LN0)18 protein–protein interaction. Helix α1 of VGL4 binds to TEAD monomer B while β-strand, helices α2 and α3 bind to TEAD monomer A. The two-helix motif of VGL4 shows potential for cyclization between D235 and K250. b Truncation study of VGL4. Fragments of the TEAD-binding motif of VGL4 were tested regarding their affinity for mTEAD4 and hTEAD1 using SPR (Kd > 100 µM: half-maximal signal was not reached at highest concentration n = 1 replicate). c Two-helix motif derived cyclic peptides obtained via lactamization of residues 235 and 250. Crosslink length-dependence of TEAD affinity was determined using mTEAD4 and hTEAD1 in an SPR assay (B: 2,4-diaminobutyric acid, O: ornithine, n = 1 replicate).
Fig. 1 Structure-based design was applied to stabilize a two-helix motif. a Crystal structure of the VGL4–TEAD (PDB: 4LN0)18 protein–protein interaction. Helix α1 of VGL4 binds to TEAD monomer B while β-strand, helices α2 and α3 bind to TEAD monomer A. The two-helix motif of VGL4 shows potential for cyclization between D235 and K250. b Truncation study of VGL4. Fragments of the TEAD-binding motif of VGL4 were tested regarding their affinity for mTEAD4 and hTEAD1 using SPR (Kd > 100 µM: half-maximal signal was not reached at highest concentration n = 1 replicate). c Two-helix motif derived cyclic peptides obtained via lactamization of residues 235 and 250. Crosslink length-dependence of TEAD affinity was determined using mTEAD4 and hTEAD1 in an SPR assay (B: 2,4-diaminobutyric acid, O: ornithine, n = 1 replicate).CC BY · PubMed Central
Fig. 2 Structural characterization of the stabilized two-helix motif was performed. a CD spectra of selected peptides and calculated helicities are shown (for details, see Methods section). Source data are provided as a Source Data file42. b X-ray crystal structure of 4E (orange) co-crystallized with mTEAD4 (grey, PDB: 6SBA) superimposed with the corresponding part of the TEAD-binding motif of VGL4 (blue/yellow, PDB: 4LN0). c 2Fo-Fc electron density map (black, contoured at σ = 1.2) of 4E (PDB: 6SBA) from top and bottom view. d Superimposition of two-helix motif from VGL4 (blue, PDB 4LN0) and peptide 4E (orange, PDB: 6SBA), side chains of residues previously identified as interacting with TEAD are shown explicitly. e Structure of 4E in complex with mTEAD4 (PDB: 6SBA) including all side chains is shown. Hotspot amino acids are highlighted (red) as determined by experimental alanine-scanning using SPR (mTEAD4) as readout. Crystal structure of the E4/mTEAD4 complex is available under PDB: 6SBA.
Fig. 2 Structural characterization of the stabilized two-helix motif was performed. a CD spectra of selected peptides and calculated helicities are shown (for details, see Methods section). Source data are provided as a Source Data file42. b X-ray crystal structure of 4E (orange) co-crystallized with mTEAD4 (grey, PDB: 6SBA) superimposed with the corresponding part of the TEAD-binding motif of VGL4 (blue/yellow, PDB: 4LN0). c 2Fo-Fc electron density map (black, contoured at σ = 1.2) of 4E (PDB: 6SBA) from top and bottom view. d Superimposition of two-helix motif from VGL4 (blue, PDB 4LN0) and peptide 4E (orange, PDB: 6SBA), side chains of residues previously identified as interacting with TEAD are shown explicitly. e Structure of 4E in complex with mTEAD4 (PDB: 6SBA) including all side chains is shown. Hotspot amino acids are highlighted (red) as determined by experimental alanine-scanning using SPR (mTEAD4) as readout. Crystal structure of the E4/mTEAD4 complex is available under PDB: 6SBA.CC BY · PubMed Central
Fig. 3 Cell permeability, protease stability, and PPI inhibition of modified peptides were investigated. a Structure of peptide 7 consisting of peptide 4E (orange) N-terminally linked via PEG2 (8-amino-3,6-dioxaoctanoyl) to the cell permeable peptide Tat (grey). b Time-dependent proteolytic stability of the peptides in cell culture media buffer containing 10% foetal bovine serum (c(peptide) = 30 µM) (n = 2 technically independent replicates, error bars = SD). c Intracellular concentration of unlabelled peptides investigated by mass spectrometry (90 min incubation at c(peptide) = 25 µM). Peptides 4 and 4E have concentrations below the lower limit of quantification (LLOQ), therefore they were not detected (n = 2 biologically independent replicates, error bars = SEM). d In vitro competition pull-down is performed with a complex of recombinant GST-hTEAD1 and two-helix motif peptides in presence of synthetic biotin-VGL4 immobilized on streptavidin magnetic beads; after incubation for 2.5 h, hTEAD1 pull-down is analysed by SDS-PAGE (n = 1 replicate). Source data are provided as a Source Data file.
Fig. 3 Cell permeability, protease stability, and PPI inhibition of modified peptides were investigated. a Structure of peptide 7 consisting of peptide 4E (orange) N-terminally linked via PEG2 (8-amino-3,6-dioxaoctanoyl) to the cell permeable peptide Tat (grey). b Time-dependent proteolytic stability of the peptides in cell culture media buffer containing 10% foetal bovine serum (c(peptide) = 30 µM) (n = 2 technically independent replicates, error bars = SD). c Intracellular concentration of unlabelled peptides investigated by mass spectrometry (90 min incubation at c(peptide) = 25 µM). Peptides 4 and 4E have concentrations below the lower limit of quantification (LLOQ), therefore they were not detected (n = 2 biologically independent replicates, error bars = SEM). d In vitro competition pull-down is performed with a complex of recombinant GST-hTEAD1 and two-helix motif peptides in presence of synthetic biotin-VGL4 immobilized on streptavidin magnetic beads; after incubation for 2.5 h, hTEAD1 pull-down is analysed by SDS-PAGE (n = 1 replicate). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 Cellular activity of 7 in RKO cells and in primary juvenile cardiomyocytes was investigated. a Schematic overview of the Hippo signalling pathway. Presence of 7 inhibits formation of repressor complex, thereby supporting TEAD-dependent target gene expression. b Proximity ligation assay (PLA) to probe the YAP–TEAD interaction in RKO cells. Peptides were incubated for 24 h (c = 30 µM). Untreated cells were used as control. PLA was performed using YAP and TEAD antibodies (centre: mean, whiskers: minimum to maximum, box: lower to upper quartile; for details, see Methods section, n = 3 biologically independent experiments with two n = 2 technically independent replicates each). c Representative images of wound healing assay of RKO cells treated with different peptides (c = 30 µM, cell front is represented before (blue) and after 48 h treatment (yellow)). The experiment was performed in n = 3 biologically independent replicates each with n = 3 technically independent replicates. d Effects of 7 on YAP distribution (nucleus/cytosol). Juvenile rat heart cells were treated with peptide 7 (10 µM) or DMSO vehicle for 4 h, fixed and stained (DAPI, αActinin, YAP). Nuclear and cytosolic YAP levels in cardiomyocytes were quantified by image analysis (primary juvenile (P5–P6) rat cardiomyocytes, n = 3–4 biologically independent replicates, error bars = SEM). e qPCR analysis of the TEAD target genes. Bars represent the mRNA fold-changes of CYR61, CTGF, SEPINE1, ANKRD1, and CCNA2 genes after 18 h treatment with 7 (red) relative to Tat (cardiomyocytes generated from human ES cell line (H7), n = 2 biological replicates with n = 3 technical replicates each). f High-content imaging-based analysis of cell cycle activity in primary juvenile (P5–P6) rat cardiomyocytes after 4 days. Untreated (–, DMSO) or treated (c = 10 µM) with p38MAPK inhibitor SB203580 (SB), GSK3β inhibitor CHIR99021 (CHIR), 4E or 7 (plotted relative to DMSO-treated cells, 6 biological replicates, error bars = SEM). g Dose-dependent cell cycle stimulation after 4-day treatment with 7 (primary juvenile (P5–P6) rat cardiomyocytes, plotted relative to DMSO-treated cells, n = 3 biological replicates, error bars = SEM). For all the experiments, statistical significances were determined by Student’s paired t test; p < 0.05 was considered statistically significant (p < 0.05 = *; p < 0,01 = **; p < 0.001 = ***, p < 0.0001 = ****) and source data are provided as a Source Data file.
Fig. 4 Cellular activity of 7 in RKO cells and in primary juvenile cardiomyocytes was investigated. a Schematic overview of the Hippo signalling pathway. Presence of 7 inhibits formation of repressor complex, thereby supporting TEAD-dependent target gene expression. b Proximity ligation assay (PLA) to probe the YAP–TEAD interaction in RKO cells. Peptides were incubated for 24 h (c = 30 µM). Untreated cells were used as control. PLA was performed using YAP and TEAD antibodies (centre: mean, whiskers: minimum to maximum, box: lower to upper quartile; for details, see Methods section, n = 3 biologically independent experiments with two n = 2 technically independent replicates each). c Representative images of wound healing assay of RKO cells treated with different peptides (c = 30 µM, cell front is represented before (blue) and after 48 h treatment (yellow)). The experiment was performed in n = 3 biologically independent replicates each with n = 3 technically independent replicates. d Effects of 7 on YAP distribution (nucleus/cytosol). Juvenile rat heart cells were treated with peptide 7 (10 µM) or DMSO vehicle for 4 h, fixed and stained (DAPI, αActinin, YAP). Nuclear and cytosolic YAP levels in cardiomyocytes were quantified by image analysis (primary juvenile (P5–P6) rat cardiomyocytes, n = 3–4 biologically independent replicates, error bars = SEM). e qPCR analysis of the TEAD target genes. Bars represent the mRNA fold-changes of CYR61, CTGF, SEPINE1, ANKRD1, and CCNA2 genes after 18 h treatment with 7 (red) relative to Tat (cardiomyocytes generated from human ES cell line (H7), n = 2 biological replicates with n = 3 technical replicates each). f High-content imaging-based analysis of cell cycle activity in primary juvenile (P5–P6) rat cardiomyocytes after 4 days. Untreated (–, DMSO) or treated (c = 10 µM) with p38MAPK inhibitor SB203580 (SB), GSK3β inhibitor CHIR99021 (CHIR), 4E or 7 (plotted relative to DMSO-treated cells, 6 biological replicates, error bars = SEM). g Dose-dependent cell cycle stimulation after 4-day treatment with 7 (primary juvenile (P5–P6) rat cardiomyocytes, plotted relative to DMSO-treated cells, n = 3 biological replicates, error bars = SEM). For all the experiments, statistical significances were determined by Student’s paired t test; p < 0.05 was considered statistically significant (p < 0.05 = *; p < 0,01 = **; p < 0.001 = ***, p < 0.0001 = ****) and source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 66

Metadata

Authors
Adihou, H., Gopalakrishnan, R., Förster, T., Guéret, S. M., Gasper, R., Geschwindner, S., Carrillo García, C., Karatas, H., Pobbati, A. V., Vazquez‐Chantada, M., Davey, P., Wassvik, C. M., Pang, J. K. S., Soh, B. S., Hong, W., Chiarparin, E., Schade, D., Plowright, A. T., Valeur, E., Lemurell, M., Grossmann, T. N., & Waldmann, H.
Affiliations
  • AstraZeneca (Sweden) (SE)
  • AstraZeneca (Germany) (DE)
  • Max Planck Institute of Molecular Physiology (DE)
  • Agency for Science, Technology and Research (SG)
  • AstraZeneca (United Kingdom) (GB)
  • Christian-Albrechts-Universität zu Kiel (DE)
  • Vrije Universiteit Amsterdam (NL)
  • TU Dortmund University (DE)
Corresponding author
  • Grossmann, Tom N.
  • Waldmann, Herbert
Venue
Nature Communications
Published
2020-10-27
Volume
11
Issue
1
Pages
5425-5425
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3096898590
Cited by
58
References
42
Citations by year
2026: 1 · 2025: 10 · 2024: 9 · 2023: 12 · 2022: 14 · 2021: 11 · 2020: 1
FWCI
4.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • VU Research Portal (publishedVersion, other-oa)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion, other-oa)
  • National University of Singapore (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • MPG.PuRe (Max Planck Society) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Leibniz-Institut für Arbeitsforschung an der TU Dortmund
  • Paul Scherrer Institut
  • H2020 European Research Council (678623)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
Hippo signaling pathway, protein-protein interaction inhibitors, TEAD, peptidomimetics, cell-penetrating peptides, cell proliferation
MeSH terms
Hippo Signaling Pathway, TEA Domain Transcription Factors, DNA-Binding Proteins, Humans, Nuclear Proteins, Protein Binding, Transcription Factors, Signal Transduction, Protein Serine-Threonine Kinases, Protein Structure, Tertiary, Peptidomimetics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A protein tertiary structure mimetic modulator of the Hippo signalling pathway. https://app.cochat.ai/papers/10.1038/s41467-020-19224-8
The paper
Adihou, H., Gopalakrishnan, R., Förster, T., Guéret, S. M., Gasper, R., Geschwindner, S., Carrillo García, C., Karatas, H., Pobbati, A. V., Vazquez‐Chantada, M., Davey, P., Wassvik, C. M., Pang, J. K. S., Soh, B. S., Hong, W., Chiarparin, E., Schade, D., Plowright, A. T., Valeur, E., . . . Waldmann, H. (2020). A protein tertiary structure mimetic modulator of the Hippo signalling pathway. Nature Communications. https://doi.org/10.1038/s41467-020-19224-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.